Following Milestone FDA Approval, MSK Researchers Address Resistance to Larotrectinib through Next-Generation TRK-Targeted Therapeutic

LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase...
1-Apr-2019 4:05 PM EDT Add to Favorites

MSK Researchers Identify a New Method to “Genetically Cloak” Cancer-Fighting Immune Cells

During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness.
29-Jan-2019 12:05 PM EST Add to Favorites

New Study Reveals Gut Microbes May Help Protect People Having a Bone Marrow Transplant

Researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from a new study that looks at the likelihood of complications for people undergoing bone marrow transplants (BMTs). The observational study found that people with lower...
3-Dec-2018 10:05 AM EST Add to Favorites

Memorial Sloan Kettering Researchers at ASH Annual Meeting

MSK experts in CAR-T therapy, immunotherapy, leukemia, lymphoma, blood and marrow stem cell transplantation, and more, are also available to comment on meeting news.
29-Nov-2018 3:05 PM EST Add to Favorites

Fecal Transplants Proven to Restore Health-Promoting Bacteria

A randomized clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has shown that fecal microbiota transplants (FMTs)
8-Oct-2018 3:55 PM EDT Add to Favorites

Memorial Sloan Kettering Researchers Build a New Model of Genetically Engineered Immune Cells That May Combat Solid Tumors in the Future

Scientists at Memorial Sloan Kettering Cancer Center (MSK) announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors.
14-Aug-2018 12:05 PM EDT Add to Favorites

Distinguished Chemist Selected to Lead the Tri-Institutional Therapeutics Discovery Institute

Peter T. Meinke, PhD, an accomplished chemist with more than 30 years of industry and academic experience, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute.
12-Jun-2018 12:05 PM EDT Add to Favorites

Genomic Markers Can Predict the Presence of Lynch Syndrome across a Broad Spectrum of Cancers

Microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies can predict Lynch syndrome (LS) across tumor types, according to researchers from Memorial Sloan Kettering Cancer Center (MSK), who presented this retrospective data...
2-Jun-2018 8:00 AM EDT Add to Favorites

see all news